This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease. Patients are not on dialysis and are naive to, or have received erythropoiesis stimulating agent treatment. Data will be collected for 10 months.
Study Type
OBSERVATIONAL
Enrollment
340
Nemocnice Novy Jicin; Dialyzacni Stredisko
Nový Jičín, Czechia
Average Dose of MIRCERA at Entry Level
The average dose of MIRCERA, measured in micrograms (µg) at entry level was reported.
Time frame: Baseline
Average Dose of MIRCERA During Titration Period Month 1
The average dose of MIRCERA, measured in microgram (µg) at each month interval during the titration period was reported.
Time frame: Month 1
Average Dose of MIRCERA During Titration Period Month 2
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the titration period was reported.
Time frame: Month 2
Average Dose of MIRCERA During Titration Period Month 3
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the titration period was reported.
Time frame: Month 3
Average Dose of MIRCERA During Titration Period Month 4
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the titration period was reported.
Time frame: Month 4
Average Dose of MIRCERA During Maintenance Period Month 1
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 5 (Maintenance Period Month 1)
Average Dose of MIRCERA During Maintenance Period Month 2
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 6 (Maintenance Period Month 2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Average Dose of MIRCERA During Maintenance Period Month 3
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 7 (Maintenance Period Month 3)
Average Dose of MIRCERA During Maintenance Period Month 4
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 8 (Maintenance Period Month 4)
Average Dose of MIRCERA During Maintenance Period Month 5
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 9 (Maintenance Period Month 5)
Average Dose of MIRCERA During Maintenance Period Month 6
The average dose of MIRCERA, measured in micrograms (µg) at each month interval during the maintenance period was reported.
Time frame: Month 10 (Maintenance Period Month 6)
The Mean Hemoglobin (Hb) Level During Titration Period
The hemoglobin level was measured in grams per liter (g/L) at entry level and after each month of treatment with MIRCERA. The study did not distinguish between erythropoiesis stimulating agent naive and erythropoiesis stimulating agent treated participants, and collected the overall data (Hb level) before/after administration of MIRCERA.
Time frame: Baseline, Month 1, 2, 3, 4
The Mean Hemoglobin (Hb) Level During Maintenance Period
The hemoglobin level was measured in grams per liter (g/L) after each month of treatment with MIRCERA. The study did not distinguish between erythropoiesis stimulating agent naive and erythropoiesis stimulating agent treated participants, and collected the overall data (Hb level) before/after administration of MIRCERA
Time frame: Month 5, 6, 7, 8, 9, 10